Patents by Inventor Yanshen KANG

Yanshen KANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
    Publication number: 20230279117
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
    Type: Application
    Filed: October 27, 2022
    Publication date: September 7, 2023
    Inventors: Kang LI, Jing SONG, Tong ZHANG, Yucheng LI, Zhiying REN, Yanshen KANG
  • Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
    Patent number: 11512132
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: November 29, 2022
    Assignee: BEIGENE, LTD.
    Inventors: Kang Li, Jing Song, Tong Zhang, Yucheng Li, Zhiying Ren, Yanshen Kang
  • ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
    Publication number: 20200283527
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
    Type: Application
    Filed: December 5, 2019
    Publication date: September 10, 2020
    Inventors: Kang LI, Jing SONG, Tong ZHANG, Yucheng LI, Zhiying REN, Yanshen KANG
  • Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
    Patent number: 10544225
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: January 28, 2020
    Assignee: BEIGENE, LTD.
    Inventors: Kang Li, Jing Song, Tong Zhang, Yucheng Li, Zhiying Ren, Yanshen Kang
  • ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
    Publication number: 20180215825
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
    Type: Application
    Filed: July 1, 2015
    Publication date: August 2, 2018
    Inventors: Kang LI, Jing SONG, Tong ZHANG, Yucheng Li, Zhiying REN, Yanshen KANG